Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D207/333—Radicals substituted by oxygen or sulfur atoms

Definitions

• the present invention relates to novel 3,4-bis (catechol) pyrrole-N-substituted compounds, their preparation and use in the treatment of cancer.
• Tumor cells originate from innate or acquired chromosomal changes resulting from translocation, gene amplification, retroviral insertion, mutation, genetic deletion, as well as epigenetic disorders. These abnormalities affect many genes involved in cell cycle control, apoptosis, growth and survival, as well as repair, DNA stabilization and detoxification genes.
• chemoresistance has emerged. They differ from the known mechanisms of chemoresistance linked mainly to the expression of the drug expulsion membrane system: ABC protein (ATP-Binding Cassette) of which the MDR1 (Multi Drug Resistance-1) system is part.
• ABC protein ATP-Binding Cassette
• MDR1 Multi Drug Resistance-1
• the cancer cells develop a chemoresistance by stimulating the survival pathway, associated with the inhibition pro-apoptotic pathways.
• This survival pathway is activated by receptors with tyrosine kinase activity (EGFR, PDGFR, IGFR), themselves activated by growth factors.
• PI3K proteins Phosphatidyl inositol 3 OH kinase
• PDK phosphoinositide dependent tyrosine kinase
• Akt serine / threonine protein kinase PKB
• PTEN phosphatase and tensin homologue deleted on chromosome 10
• FOXO forkhead box O
• mTOR mimerase inhibitor
• the survival pathway has a protective effect against apoptosis and can induce autophagy.
• One of the main objectives of the pharmacology of anticancer drugs is therefore the permanent search for new drugs likely to manifest a better therapeutic efficacy, through specific molecular targets, associated with the absence of drug resistance as well as the absence of toxicity on healthy cells.
• the present invention relates to the novel 3,4-bis (catechol) pyrrole-N-substituted compounds of general formula (I) below, their preparation as well as their antimitotic action and their mode of action with respect to cells. cancerous.
• n is an integer from 0 to 3, preferably from 0 to 2;
• n is an integer from 0 to 3, preferably from 0 to 2;
• - A represents a hydrocarbon chain, saturated or unsaturated, linear or branched, comprising from 1 to 10 carbon atoms;
• R 1 and R 2 each represent, independently of one another, a hydrogen atom, a CO- (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, phenyl or phenyl group (Ci - C 6 ) -alkyl, where R 1 and R 2 together with the nitrogen atom carrying them, form a 5 to 15-membered heterocycle, optionally substituted by a (C 1 -C 6 ) alkyl group;
• the present invention relates to the compound of formula (Ia) and its use as a medicament for the treatment of cancer.
• radicals R 1 and R 2 form, together with the nitrogen atom carrying them, a heterocycle which is saturated and which comprises no other heteroatom other than the nitrogen atom which bears R 1 and R 2 . More particularly, R 1 and R 2 together with the nitrogen atom carrying them form a heterocycle of 10 to 15 members, preferably 13 members.
• the A chain is a linear saturated hydrocarbon chain comprising 3 to 6 carbon atoms, preferably 3 carbon atoms.
• the present invention relates in particular to the compound of formula (1) or a pharmaceutically acceptable acid salt thereof
• the compound (1) used at concentrations flanking its IC50, shows no cytotoxicity with respect to normal human cells.
• the present invention also extends to a pharmaceutical composition
• a pharmaceutical composition comprising at least one compound of general formula (I), more particularly the compound (Ia) and preferentially the compound (1), with at least one pharmaceutically acceptable excipient.
• the present invention relates to the use of the compounds (I), more particularly (Ia) and (I), as a medicament for the treatment of cancer, in particular lung, breast, liver and stomach cancer.
• cancer in particular lung, breast, liver and stomach cancer.
• the invention also relates to a process for preparing a compound of formula (I), more particularly (la) and (1) comprising:
• n and m, EAG, R 1, R 2 and A are as previously defined with respect to the general formula (I), and X represents a halogen atom, to give a compound of the formula (I).
• the halide (III) and the amine (II) are first reacted together before adding the aldehyde (IV).
• the radical X of the halide (III) is a chlorine, bromine or iodine atom.
• the compound 5,5 '- (1- (3- (azacyclotridecan-1-yl) propyl) -1H-pyrrole-3,4-diyl) bis (3-nitrobenzene-1,2-diol) (1) was prepared by the condensation of the phenacyl halide 3 with the primary amine 2 and phenylacetaldehyde 4, shown below:
• N- (3-aminopropyl) azatricyclodecane (2) ((a) G. Koren-Goldshlager, Y. Kashman, M. Schleyer, J. Nat Prod, 1998, 61, 282-284; (b) DE Williams , KS Craig, B. Patrick, LM McHardy, R. van Soest, M. Roberge, RJ Andersen, J. Org Chem., 2002, 67, 245-258) was obtained from commercial laurolactam according to Scheme 1 below:
• Azacyclotridecane ((a) JE Baldwin, HR Vollmer, V. Lee, Tetrahedron Lett., 1999, 40, 5401-5404; (b) Weston MH, K. Nakajima, TG Back, J. Org. Chem., 2008, 73 , 4630-4637).
• Phenacyl bromide 3 (1.23 g, 4.2 mmol) and NaI (3.2 g, 21 mmol) are added to a solution of amine 2 (1 g, 4.2 mmol) in DMSO ( 20 mL) at RT under argon and the reaction mixture is stirred for 15 min at RT.
• a solution of the aldehyde 4 (900 mg, 4.3 mmol) in methanol (60 mL) is then added and the reaction mixture is stirred for 16 h at RT. It is extracted with CH 2 Cl 2 and the organic phase is washed with saturated NaHCO 3 solution , brine, dried over Na 2 SO 4 , evaporated under reduced pressure and chromatographed on silica gel (CH elution gradient).
• the biological activity of the compound (1) was studied in vitro on 3 different cancer cell lines:
• HUVEC human vascular umbilical endothelial cells
• HFDPC skin papillary cells derived from human hair follicles.
• the cells selected for this study were incubated at 37 ° C in the presence of compound (1) added to the culture medium at different concentrations and at different times.
• the effect of the compound (1) on the growth of HCT-116, U87 and K562 cells was evaluated using a cell growth test (CellTiter-Blue Cell Viability Assay, Promega).
• the growth curves as well as the IC50 values (concentration of the compound which induces the 50% decrease in cell growth) determined after 72 hours of the treatment of the cells with the compound (1) are presented in FIG. nM for HCT-116 cells, 45 nM for U87 cells and 70 nM for K562.
• Figure 2 shows the effect of compound (I) on the number and viability of HCT 116 cells as a function of its concentration and treatment time.
• the results presented in FIG. 2a show that the number of cells decreases as a function of the concentration and the treatment time with the compound (1).
• the compound (1) at a concentration of 25 nM already exhibits an activity as early as 24 hours of treatment by reducing the number of cells by 40%, going up to more than 80% inhibition as early as 48 hours for concentrations greater than 1%. IC50.
• This inhibitory effect is, however, associated with a lack of change in cell viability ( Figure 2b). This indicates that the action of the compound (1) is cytostatic and non-cytotoxic.
• IC50 values are thus up to 300 times higher for normal cells compared to those obtained for cancer cells. This clearly indicates that malignant cells are significantly more sensitive to the action of compound (1) than healthy cells.
• HCT-116 cells treated for 24 hours were analyzed to evaluate the activity of caspases 3 and 7 and mitochondrial transmembrane potential modification.
• JC-1 is a lipophilic anionic compound that selectively enters the mitochondria, whose color changes from green to red when the transmembrane potential increases. In contrast to healthy cells, apoptotic cells have a weak ⁇ which is associated with a strong green color of the JC-1 probe.
• HCT-116 with the compound (1) at varying concentrations of 25 nM to 100 nM does not significantly modify ⁇ . All of these results indicate that the compound (1) does not induce the caspase-dependent apoptotic pathway (programmed type I cell death).
• the HCT-116 cells were treated with the compound (1) at different doses for 24 hours.
• the cell extracts were then subjected to Western blot analysis to visualize the expression of the LC3-II protein.
• the LC3 protein exists in the cell either in cytosolic form (LC3-I) or associated with phagosomes (LC3-II). The latter is the marker of the autophagic reaction.
• Peroxiredoxin protein is an enzyme with peroxidase activity, controlling the concentration of intracellular hydrogen peroxide (H 2 0 2 ).
• H 2 0 2 intracellular hydrogen peroxide
• DCF-DA 2 ', 7'-dichlorofluorescein diacetate, Sigma
• Hydrogen peroxide is a second intracellular messenger. It regulates, depending on its concentration, many functions such as proliferation or apoptosis. A reduction in its concentration is associated with a decrease in proliferation.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47425104

Family Applications (1)

Country Status (8)

Families Citing this family (2)

Citations (2)

Family Cites Families (3)

• 2012
  • 2012-10-16 FR FR1259868A patent/FR2996847B1/fr not_active Expired - Fee Related
• 2013
  • 2013-10-14 EP EP13779187.7A patent/EP2909171B1/fr not_active Not-in-force
  • 2013-10-14 ES ES13779187.7T patent/ES2608781T3/es active Active
  • 2013-10-14 JP JP2015537212A patent/JP6423349B2/ja not_active Expired - Fee Related
  • 2013-10-14 WO PCT/EP2013/071445 patent/WO2014060366A1/fr not_active Ceased
  • 2013-10-14 US US14/435,768 patent/US9546159B2/en not_active Expired - Fee Related
  • 2013-10-14 CA CA2888379A patent/CA2888379A1/fr not_active Abandoned
  • 2013-10-14 AU AU2013331764A patent/AU2013331764B2/en not_active Ceased

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events